Rare diseases
Investigational molecules
Locations
39 Avenue De La Liberte, Bp 60535, 68024 Colmar, France
Centre Hospitalier De Colmar in Colmar, France specialises in clinical trials of conditions such as Non-small cell lung cancer stage IV, Colon cancer, Chronic kidney disease, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.
The center is at the forefront of cardiovascular research, focusing on innovative treatments for acute myocardial infarction and advanced chronic kidney disease. The institution is pioneering studies on the efficacy of novel therapies like evolocumab and rivaroxaban to improve patient outcomes.
These studies aim to redefine treatment protocols and enhance the quality of life for patients with complex cardiovascular conditions.
Our center is a leader in oncology, with a strong emphasis on non-small cell lung cancer, metastatic colorectal cancer, and HPV-induced malignancies. We are exploring cutting-edge therapies, including pembrolizumab and regorafenib, to improve survival rates and quality of life for cancer patients.
Our research is instrumental in developing personalized treatment plans and advancing the field of cancer immunotherapy.
The center is advancing the field of neurology with a focus on Alzheimer's Disease Psychosis. Our research on ACP-204 aims to provide new insights into managing psychosis in Alzheimer's patients, enhancing their cognitive function and overall well-being.
These efforts are crucial in developing effective therapies that address the complex needs of patients with neurodegenerative disorders.
Our institution is pioneering research in respiratory diseases, particularly focusing on Chronic Obstructive Pulmonary Disease (COPD) and acute respiratory distress syndrome (ARDS). We are evaluating the efficacy of treatments like tozorakimab and dornase alfa to reduce exacerbations and improve patient outcomes.
Our research is vital in developing new therapeutic strategies to manage and treat severe respiratory conditions.
The center is dedicated to advancing treatments for autoimmune diseases such as polymyalgia rheumatica and immune thrombocytopenia. Our studies on secukinumab and rituximab are paving the way for more effective management of these chronic conditions.
These research initiatives are crucial in improving the quality of life for patients with persistent autoimmune disorders.
Clinical trials currently enrolling participants at this site.
A Phase III Study of Lenbelintide in Adults with Obesity or Overweight and Weight‑Related Comorbidity Without Type 2 Diabetes
FranceCarboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease
FranceOne-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease
FranceLong-term Safety Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease and History of Exacerbations
FranceStudy of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk
FranceStudy of immunosuppression reduction in kidney transplant patients with septic shock or respiratory failure receiving drug combination therapy in intensive care
FranceStudy on the Effects of Methylphenidate on Brain Function in Adults with ADHD, with or without Mood Disorders, Compared to Placebo
FranceStudy on Rituximab for Patients with Rheumatoid Arthritis: Comparing 200 mg and 1g Doses for Maintenance Treatment
FranceStudy on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer
FranceStudy on the Effectiveness of Oxybutynin for Children with Overactive Neurogenic Bladder Due to Spina Bifida
FranceStudy Comparing Rifabutin and Rifampicin for Adults with Staphylococcal Prosthetic Joint Infection Using DAIR Strategy
FranceStudy Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX
FranceGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
